Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #662 | June 10, 2016  

2016 National Patient Education Conference Updates

2016 National ConferenceWe are excited to announce that Mary Woolley, president and CEO, Research!America will be our opening keynote speaker.  Ms. Woolley will present Turning a Moment into a Movement: Your role in advocacy for Research on Friday, July 29.

We are also thrilled that Andrew Botieri, Founder of Total Peak Performance, will be our closing keynote speaking on Sunday, July 30.  Mr. Botieri will present "Got Adversity?"

The 18th annual National Patient Education Conference offers educational and networking opportunities for people living with scleroderma, their caregivers, family members and friends.  We also offer a kids program at the conference that is open to younger patients, their siblings or even the child of an adult patient.

Space is limited!  The discounted room rate is available during the conference as well as three days before and after, subject to availability, and is not guaranteed after July 7, 2016, nor if room block has sold out.

Click here for more conference info >>

 

Beta Sigma Phi Continues Its Support of the Scleroderma Foundation

 beta2016.JPGThe California Councils of Beta Sigma Phi held their annual statewide convention in Bakersfield, California, May 12-15, 2016.  The sisters of Beta Sigma Phi have been supporting the work and mission of the Scleroderma Foundation since 1980. In fact, they were the first major, national organization to “adopt” scleroderma as a cause when the California Councils decided to support what was then the United Scleroderma Foundation. Since 1980, the California Councils and the Beta Sigma Phi international endowment have contributed over three quarters of a million dollars to support the Scleroderma Foundation and its Research Program.

Scleroderma Foundation National Director of Development and Research Tracey O’Connell Sperry attended this year’s celebration and had the opportunity to thank the members of Beta Sigma Phi for their continued generosity and support of the Foundation. She also reported on advances in scleroderma research. 

The relationship with Beta Sigma Phi began with one person who knew someone living with scleroderma and brought this cause to the forefront of the councils. The California councils support four causes annually, and we are proud of this long-standing relationship that, in addition to providing financial support, has raised awareness over the past 36 years. 



Video:  Understanding Lung Problems

6816playbutton.jpgThe Federation of European Scleroderma Associations (FESCA), has released a series of videos that were recorded at the 4th Systemic Sclerosis World Congress earlier this year.  The workshops cover a variety of different topics and features.  This session addresses understanding lung problems and struggles with breathing.

Click here to watch >>

Applying for Social Security Disability Benefits

ssa-disability-benefits.jpgSocial Security’s disability program provides medical and financial support to disabled individuals and their families in a time of need. The Social Security Act sets out a strict definition of disability.

Click here for more >>


 


 
Quick Links
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Home
facebook_32.png
twitter_32.png
Youtube_32x32.png

Actelion 2016 sponsor
2016 Bayer Logo
2016 Bronze National Sponsor Reata
2016 Gilead Silver Conference Sponsor
Genentech
United Therapeutics Logo
 

 

Advertisement

Sencis Ad - eLetter

We are also excited to announce our closing keynote speaker!  Andrew Botieri, Founder of Total Peak Performance, will present "Got Adversity?"

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2024 All rights reserved.